|
1
|
Brody H: Colorectal cancer. Nature.
521:S12015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paulson EC, Veenstra CM, Vachani A, Ciunci
CA and Epstein AJ: Trends in surveillance for resected colorectal
cancer, 2001–2009. Cancer. 121:3525–3533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Vugt JL, Reisinger KW, Derikx JP,
Boerma D and Stoot JH: Improving the outcomes in oncological
colorectal surgery. World J Gastroenterol. 20:12445–12457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prorokov VV, Vlasov OA and Tupitsyn NN:
Current state of the problem of treatment and prognosis of
colorectal cancer. Vopr Onkol. 60:28–33. 2014.In Russian.
|
|
5
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
6
|
Vignali A and De Nardi P:
Multidisciplinary treatment of rectal cancer in 2014: Where are we
going? World J Gastroenterol. 20:11249–11261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Binefa G, Rodríguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahmed S, Johnson K, Ahmed O and Iqbal N:
Advances in the management of colorectal cancer: From biology to
treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morris V and Kopetz S: Clinical biomarkers
in colorectal cancer. Clin Adv Hematol Oncol. 11:768–776. 2013.
|
|
10
|
Chen Y, Thelin WR, Yang B, Milgram SL and
Jacobson K: Transient anchorage of cross-linked
glycosyl-phosphatidylinositol-anchored proteins depends on
cholesterol, Src family kinases, caveolin, and phosphoinositides. J
Cell Biol. 175:169–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu N, Fang XD and Vadis Q: CD73 as a
novel prognostic biomarker for human colorectal cancer. J Surg
Oncol. 106:918–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang
S, Yin L and Zhou P: RNAi-mediated CD73 suppression induces
apoptosis and cell-cycle arrest in human breast cancer cells.
Cancer Sci. 101:2561–2569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao ZW, Dong K and Zhang HZ: The roles of
CD73 in cancer. Biomed Res Int. 2014:4606542014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Häusler SF, Montalbán del Barrio I,
Strohschein J, Chandran PA, Engel JB, Hönig A, Ossadnik M, Horn E,
Fischer B, Krockenberger M, et al: Ectonucleotidases CD39 and CD73
on OvCA cells are potent adenosine-generating enzymes responsible
for adenosine receptor 2A-dependent suppression of T cell function
and NK cell cytotoxicity. Cancer Immunol Immunother. 60:1405–1418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stagg J, Divisekera U, McLaughlin N,
Sharkey J, Pommey S, Denoyer D, Dwyer KM and Smyth MJ: Anti-CD73
antibody therapy inhibits breast tumor growth and metastasis. Proc
Natl Acad Sci USA. 107:1547–1552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Beavis PA, Stagg J, Darcy PK and Smyth MJ:
CD73: A potent suppressor of antitumor immune responses. Trends
Immunol. 33:231–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stagg J, Beavis PA, Divisekera U, Liu MC,
Möller A, Darcy PK and Smyth MJ: CD73-deficient mice are resistant
to carcinogenesis. Cancer Res. 72:2190–2196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang B: CD73 promotes tumor growth and
metastasis. Oncoimmunology. 1:67–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Resta R and Thompson LF: T cell signalling
through CD73. Cell Signal. 9:131–139. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin D, Fan J, Wang L, Thompson LF, Liu A,
Daniel BJ, Shin T, Curiel TJ and Zhang B: CD73 on tumor cells
impairs antitumor T-cell responses: A novel mechanism of
tumor-induced immune suppression. Cancer Res. 70:2245–2255. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knapp K, Zebisch M, Pippel J, El-Tayeb A,
Müller CE and Sträter N: Crystal structure of the human
ecto-5′-nucleotidase (CD73): Insights into the regulation of
purinergic signaling. Structure. 20:2161–2173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deaglio S and Robson SC: Ectonucleotidases
as regulators of purinergic signaling in thrombosis, inflammation,
and immunity. Adv Pharmacol. 61:301–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Young A, Mittal D, Stagg J and Smyth MJ:
Targeting cancer-derived adenosine: New therapeutic approaches.
Cancer Discov. 4:879–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee MS and Kopetz S: Current and future
approaches to target the epidermal growth factor receptor and its
downstream signaling in metastatic colorectal cancer. Clin
Colorectal Cancer. 14:203–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pietrantonio F, Petrelli F, Coinu A, Di
Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi
I, Lonati V, et al: Predictive role of BRAF mutations in patients
with advanced colorectal cancer receiving cetuximab and
panitumumab: A meta-analysis. Eur J Cancer. 51:587–594. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krawczyk PA and Kowalski DM: Genetic and
immune factors underlying the efficacy of cetuximab and panitumumab
in the treatment of patients with metastatic colorectal cancer.
Contemp Oncol (Pozn). 18:7–16. 2014.
|
|
27
|
Coget J, Borrini F, Susman S and Sabourin
JC: Colorectal carcinomas in 2013: The search for powerful
prognostic markers is still on the go! Cancer Biomark. 14:145–150.
2014.PubMed/NCBI
|
|
28
|
Sideris M and Papagrigoriadis S: Molecular
biomarkers and classification models in the evaluation of the
prognosis of colorectal cancer. Anticancer Res. 34:2061–2068.
2014.PubMed/NCBI
|
|
29
|
Häusler SF, Del Barrio IM, Diessner J,
Stein RG, Strohschein J, Hönig A, Dietl J and Wischhusen J:
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted
therapy in ovarian cancer by blocking adenosine-dependent immune
evasion. Am J Transl Res. 6:129–139. 2014.PubMed/NCBI
|
|
30
|
Wu XR, He XS, Chen YF, Yuan RX, Zeng Y,
Lian L, Zou YF, Lan N, Wu XJ and Lan P: High expression of CD73 as
a poor prognostic biomarker in human colorectal cancer. J Surg
Oncol. 106:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Q, Du J and Zu L: Overexpression of
CD73 in prostate cancer is associated with lymph node metastasis.
Pathol Oncol Res. 19:811–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang LL, Tang HP, Shi GC, Wan HY, Tang W,
Hou XX, Pan LN, Shi BY and Tao LQ: CD39/CD73 and the imbalance of
Th17 cells and regulatory T cells in allergic asthma. Mol Med Rep.
8:1432–1438. 2013.PubMed/NCBI
|
|
33
|
Smyth LA, Ratnasothy K, Tsang JY, Boardman
D, Warley A, Lechler R and Lombardi G: CD73 expression on
extracellular vesicles derived from CD4+
CD25+ Foxp3+ T cells contributes to their
regulatory function. Eur J Immunol. 43:2430–2440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhi X, Wang Y, Yu J, Yu J, Zhang L, Yin L
and Zhou P: Potential prognostic biomarker CD73 regulates epidermal
growth factor receptor expression in human breast cancer. IUBMB
Life. 64:911–920. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou X, Zhi X, Zhou P, Chen S, Zhao F,
Shao Z, Ou Z and Yin L: Effects of ecto-5′-nucleotidase on human
breast cancer cell growth in vitro and in vivo. Oncol Rep.
17:1341–1346. 2007.PubMed/NCBI
|
|
36
|
Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou
Z and Yin L: RNA interference of ecto-5′-nucleotidase (CD73)
inhibits human breast cancer cell growth and invasion. Clin Exp
Metastasis. 24:439–448. 2007. View Article : Google Scholar
|
|
37
|
Ring A, Kim YM and Kahn M: Wnt/catenin
signaling in adult stem cell physiology and disease. Stem Cell Rev.
10:512–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JK, Park SR, Jung BK, Jeon YK, Lee YS,
Kim MK, Kim YG, Jang JY and Kim CW: Exosomes derived from
mesenchymal stem cells suppress angiogenesis by down-regulating
VEGF expression in breast cancer cells. PLoS One. 8:e842562013.
View Article : Google Scholar
|
|
39
|
Gopalakrishnan N, Saravanakumar M,
Madankumar P, Thiyagu M and Devaraj H: Colocalization of β-catenin
with Notch intracellular domain in colon cancer: A possible role of
Notch1 signaling in activation of cyclinD1-mediated cell
proliferation. Mol Cell Biochem. 396:281–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Horst D: Plasticity of WNT signaling
activity in colorectal cancer. Pathologe. 33(Suppl 2): 194–197.
2012.In German. View Article : Google Scholar
|
|
41
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang L, Tang S, Wang Y, Xu S, Yu J, Zhi X,
Ou Z, Yang J, Zhou P and Shao Z: Ecto-5′-nucleotidase (CD73)
promotes tumor angiogenesis. Clin Exp Metastasis. 30:671–680. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi
X, Yin L, Shao Z, Ou Z and Zhou P: Ecto-5′-nucleotidase promotes
invasion, migration and adhesion of human breast cancer cells. J
Cancer Res Clin Oncol. 134:365–372. 2008. View Article : Google Scholar
|
